Median survival among patients with “”active”" treatment did not

Median survival among patients with “”active”" treatment did not show significant differences (log rank test: P > 0.05). Overall median survival was 15.1 months. Median survival rates of the group receiving long-acting

octreotide [Sandostatin LAR], TACE, multimodal therapy and Selleckchem YH25448 palliative care were 22.4, 22.0, 35.5 and 2.9 months, respectively (Table 2). Survival rates of patients with “”active”" treatment (long-acting octreotide [Sandostatin LAR], TACE or multimodal therapy) were significantly higher than of patients who received palliative care only (log rank test: P = 0.00043, P = 0.00151, P = 0.00005). Median survival among patients with various “”active”" treatment forms did not show significant differences (log rank test: PX-478 cost P > 0.05). The 1 year survival rate in the long-acting octreotide [Sandostatin LAR] group was 64% and in patients who received multimodal therapy, TACE, and palliative care 90%, 78% and 23%, respectively. The 2 year survival rate in the long-acting octreotide [Sandostatin

LAR] group was 36% and in patients who received multimodal therapy, TACE, and palliative care 80%, 34% and 5%, respectively. Discussion In the present paper we studied GSK3326595 cell line retrospectively the influence of octreotide monotherapy (long-acting octreotide [Sandostatin LAR]) on survival of patients with hepatocellular carcinoma and compared it to BCLC stage-matched patients who received either TACE, multimodal therapy or palliative care only. Our data showed that survival rates of Oxymatrine patients with BCLC stage B and any “”active”" treatment (long-acting octreotide [Sandostatin LAR], TACE or multimodal therapy) were significantly higher as compared to patients who received palliative care only. Although survival

time of patients with BCLC stage A and “”active”" treatment (long-acting octreotide [Sandostatin LAR], TACE or multimodal therapy) were more than twice as long as of patients who received palliative care only this difference was not statistically significant. Median survival among patients with various forms of “”active”" treatment did not show significant differences (BCLC stage A and B; log rank test: P > 0.05). In particular, octreotide monotherapy showed a similar outcome compared to patients who received TACE or multimodal therapy. Kouroumalis et al [11] for the first time published a patient population with advanced liver disease (only 3.6% of the patients had Child-Pugh stage A) and HCC treated with octreotide. The treatment group had an excellent median survival of 13.0 months as compared to 4.0 months in the control group, suggesting a beneficial effect of octreotide treatment in this patient population. Similarly, Dimitroulopoulos et al [12] recently reported the results of a randomised placebo-controlled trial which showed a significantly higher survival in somatostatin receptor positive patients receiving long-acting octreotide [Sandostatin LAR] as compared to placebo.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>